Friday, February 1, 2019 Daily Archives

Vendors highlight another standout year for bioprocessing

by

Demand for bioprocessing technology remains strong as GE Healthcare, Thermo Fisher, Pall and Sartorius all report high annual growth. With the financial season in full swing, four of the major industry suppliers have reported their Q4s and end-of-year results, and all have one thing in common: high growth across their bioprocessing segments. GE Healthcare, which is being prepped to separate from parent company General Electric, reported revenues of $19 billion (€16.5 billion) for the full year, up 4%. The division…

February 1, 2019

Janssen enters $440m retinal gene therapy partnership

by

J&J has licensed a clinical stage inherited retinal disease portfolio from MeiraGTx in a deal that could be worth $440 million (€385 million). Johnson & Johnson’s Janssen division has paid $100 million upfront to MeiraGTx, a London-UK based clinical stage company, to access and codevelop the firm’s gene therapy programs. Development and sales milestones for MeiraGTx’s could net the firm a further $340 million. Under terms of the deal, the two firms aim to develop, manufacture and commercialize several candidates…

February 1, 2019

Novartis: Manufacturing volumes a barrier to $10bn insulin space

by

The manufacturing volumes needed to succeed in the insulin market are huge says Novartis, fresh from entering the space through a biosimilars partnership. Late last year, Swiss pharma firm Novartis, through its division Sandoz, partnered with Chinese manufacturer Gan & Lee in an effort to bring biosimilar insulins to the US and Europe. Sandoz told this publication at the time that Gan & Lee’s production capacity, “with attractive cost of goods sold structures,†was a major driver to the collaboration.…

February 1, 2019